Last reviewed · How we verify

Vedrop (TOCOFERSOLAN)

FDA-approved approved Small molecule

Vedrop, also known as tocofersolan, is a small molecule drug that targets glutathione S-transferase P. It is used to treat obstruction of bile duct and vitamin E deficiency. The commercial status of Vedrop is currently unknown, and it is not clear if it is patented or available as a generic. Vedrop's safety considerations are also not well-documented. Further research is needed to fully understand its pharmacological properties and clinical applications.

At a glance

Generic nameTOCOFERSOLAN
TargetAlpha-tocopherol transfer protein, Glutathione S-transferase P
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved
First approval2009

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: